Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 801–900 of 1,001
An 11-gene signature for the prediction of systemic recurrences in colon adenocarcinoma
Cai, J., Huang, X., Li, X.-L., Qin, S., Rong, Y., Chen, X., Weng, J., Zou, Y., & Lin, X. (2021) · Gastroenterology report · doi:10.1093/gastro/goab023 · Cited by 11
Liu, Y., Xu, Y., Li, X., Chen, M., Wang, X., Zhang, N., Zhang, H., & Zhang, Z. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00512-1 · Cited by 10
Hu, S., Xiao, Q., Gao, R. C., Qin, J., Nie, J., Chen, Y., Lou, J., Ding, M., Pan, Y., & Wang, S. (2024) · BMC Cancer · doi:10.1186/s12885-024-12251-4 · Cited by 10
Lin, S., Ma, L., Mo, J., Zhao, R., Li, J., Yu, M., Jiang, M., & Peng, L. (2024) · Aging · doi:10.18632/aging.205778 · Cited by 10
Yang, X., Liu, J., Wang, S., Al-Ameer, W. H. A., Ji, J., Cao, J., Dhaen, H. M. S., Lin, Y., Zhou, Y., & Zheng, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05323-3 · Cited by 11
Shen, K., Zhu, C., Wu, J., Jiang, Y., Li, P., Cao, S., Zhou, X., & Yao, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430352 · Cited by 10
Sun, W., Su, Y., & Zhang, Z. (2024) · Discover Oncology · doi:10.1007/s12672-024-01298-1 · Cited by 10
Pang, L., Sun, Q., Wang, W., Song, M., Wu, Y., Shi, X., & Shi, X. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42237 · Cited by 10
Ali, H., Bitar, M. S., Madhoun, A. S. A., Marafie, M. J., & Al‐Mulla, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171690 · Cited by 10
Liu, D. (2019) · Cellular Oncology · doi:10.1007/s13402-018-00420-0 · Cited by 10
Qin, X., & Kojima, S. (2019) · Gastrointestinal Disorders · doi:10.3390/gidisord1010014 · Cited by 10
Zhao, H., He, L., Yin, D., & Song, B. (2019) · Oncology Letters · doi:10.3892/ol.2019.10724 · Cited by 10
Rachiglio, A. M., Sacco, A., Forgione, L., Esposito, C., Chicchinelli, N., & Normanno, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00004 · Cited by 10
Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy
Frau, C., Jamard, C., Delpouve, G., Guardia, G. D. A., Machon, C., Pilati, C., Nevé, C. L., Laurent‐Puig, P., Guitton, J., Galante, P. A. F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2450 · Cited by 10
Self-citationGleizes, A. R., Triki, M., Bonnet, S., Baccari, N., Jiménez-Domínguez, G., Covinhes, A., Pirot, N., Blache, P., Yuan, R., Győrffy, B., et al. (2021) · Cancers · doi:10.3390/cancers13133192 · Cited by 10
Xu, Y., Peng, Y., Shen, M., Liu, L., Lei, J., Gao, S., Wang, Y., Lan, A., Li, H. J., & Liu, S. (2022) · Journal of Oncology · doi:10.1155/2022/1525245 · Cited by 10
Weng, M., Li, T., Zhao, J., Guo, M., Zhao, W., Gu, W., Sun, C., Yue, Y., Zhong, Z., Nan, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.950782 · Cited by 10
Zhou, J., Guo, H., Liu, L., Feng, M.-L., Yang, X., & Hao, S. (2022) · Aging · doi:10.18632/aging.204302 · Cited by 10
French, C. L., Ye, F., Revetta, F. L., Zhang, B., Coffey, R. J., Washington, M. K., Deane, N. G., Beauchamp, R. D., & Weaver, A. M. (2015) · F1000Research · doi:10.12688/f1000research.6388.1 · Cited by 10
Monica, M., Padmashree, C., & Aneja, R. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20150109 · Cited by 10
Shi, M., & Xu, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-05275-3 · Cited by 10
Optimal Bayesian Filtering for Biomarker Discovery: Performance and Robustness
pour, A. F., & Dalton, L. A. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2858814 · Cited by 10
Salehizadeh, S., Hasanzad, M., Kadijani, A. A., & Akbari, A. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00295-w · Cited by 10
Qiu, Y., Jiang, H., & Ching, W. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2992605 · Cited by 10
Saddozai, U. A. K., Wang, F., Cheng, Y., Zhang, L., Akbar, M. U., Zhu, W., Li, Y., Ji, X., & Guo, X. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100816 · Cited by 10
RP11‑619L19.2 promotes colon cancer development by regulating the miR‑1271‑5p/CD164 axis
Zhang, X., Li, S., Zhang, D., Sun, X., & Zhai, H. (2020) · Oncology Reports · doi:10.3892/or.2020.7794 · Cited by 10
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
Ghidini, M., Fusco, N., Salati, M., Khakoo, S. S., Tomasello, G., Petrelli, F., Trapani, D., & Petrillo, A. (2021) · Current Drug Targets · doi:10.2174/1389450122666210204204415 · Cited by 10
BRAFV600E augments WNT signaling in colorectal cancer via aberrant DNA methylation
Bouazzaoui, L. E., Bugter, J. M., Küçükköse, E., Verheem, A., Post, J. B., Fenderico, N., Rinkes, I. H. M. B., Snippert, H. J. G., Maurice, M. M., & Kranenburg, O. (2025) · iScience · doi:10.1016/j.isci.2025.112708 · Cited by 9
Research progress of colorectal cancer in genomic and transcriptomic at multi-level
Wen, Q., Han, S., & Cui, Y. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1533817 · Cited by 9
Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 9
Chen, M., Cai, Y., Han, F., Li, B., Zhou, X., Cui, K., Bai, W., & Li, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1620388 · Cited by 9
Yue, Y., She, X., Wenbo, D., Chen, S., Xiao, Q., Pan, B., Zhou, L., Yin, Y., Li, Y., Wang, S., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112197 · Cited by 9
Yu, K., Wang, J., Wang, Y., He, J., Hu, S., & Kuai, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05906-z · Cited by 9
Heming, C. P., & Aran, V. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104504 · Cited by 9
Wang, Z., Han, H., Zhang, C., Wu, C., Di, J., Xing, P., Qiao, X., Weng, K., Hao, H., Yang, X., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03193-7 · Cited by 9
Patrick, E., Schramm, S., Ormerod, J. T., Scolyer, R. A., Mann, G. J., Mueller, S., & Yang, J. Y. H. (2016) · Oncotarget · doi:10.18632/oncotarget.13203 · Cited by 9
A novel gene-pair signature for relapse-free survival prediction in colon cancer
Chen, P., Wang, F., Zhang, Z.-X., Nie, J.-Y., Liu, L., Feng, J., Zhou, R., Wang, H., Liu, J., & Zhao, Q. (2018) · Cancer Management and Research · doi:10.2147/cmar.s176260 · Cited by 9
Giri, A. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.620811 · Cited by 9
Kobayashi, Y., Kumamoto, K., Okayama, H., Matsumoto, T., Nakano, H., Saito, K., Matsumoto, Y., Endo, E., Kanke, Y., Watanabe, Y., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247169 · Cited by 9
Xiang, R., Fu, J., Ge, Y., Ren, J. T., Song, W., & Fu, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705537 · Cited by 9
Zhang, Y., Li, L., Chu, F., Xiao, X., Zhang, L., Li, K., & Wu, H. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610536 · Cited by 9
Liu, M., Xu, X., Peng, K., Hou, P., Yuan, Y., Li, S., Sun, X., Shi, Z., Zhang, J., Dong, Y., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00428-0 · Cited by 9
Jiang, H., Yang, B., Jiang, Y., Liu, X., Chen, D.-L., Long, F.-X., Zhu, Y., & Tang, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1025397 · Cited by 9
Identification of distinct molecular subtypes of uterine carcinosarcoma
An, Y., Wang, H., Jie, J., Tang, Y., Zhang, W., Ji, S., & Guo, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15032 · Cited by 9
SPSNet: subpopulation-sensitive network-based analysis of heterogeneous gene expression data
Belorkar, A., Vadigepalli, R., & Wong, L. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0538-1 · Cited by 9
Küçük, B., Yilmaz, E., & Çaçan, E. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06404-y · Cited by 9
van den Berg, I., Smid, M., van den Braak, R. R. J. C., van de Wiel, M. A., van Deurzen, C. H. M., de Weerd, V., Martens, J. W. M., IJzermans, J. N. M., & Wilting, S. M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13098 · Cited by 9
Intestinal Epithelial Cells Adapt to Chronic Inflammation through Partial Genetic Reprogramming
Collin, G., Foy, J., Aznar, N., Rama, N., Wierinckx, A., Saintigny, P., Puisieux, A., & Ansieau, S. (2023) · Cancers · doi:10.3390/cancers15030973 · Cited by 9
Chai, R., Su, Z., Zhao, Y., & Liang, W. H. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2036 · Cited by 9
Wen, Q., Dunne, P. D., O’Reilly, P. G., Li, G., Bjourson, A. J., McArt, D. G., Hamilton, P. W., & Zhang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13884 · Cited by 9
An, N., Zhao, C., Yu, Z., & Yang, X. C. (2018) · Oncology Letters · doi:10.3892/ol.2018.9632 · Cited by 9
Targeting the TGF-β Signaling Axis in Metastatic Colorectal Cancer: Where Do We Stand?
Papavassiliou, K. A., Cave, D. D., & Papavassiliou, A. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317101 · Cited by 9
Tête, A., Debizet, K., Rives, C., Imler, J., Safi-Stibler, S., Gales, L., Bellvert, F., Dairou, J., Hagimont, A., Burel, A., et al. (2025) · Environment International · doi:10.1016/j.envint.2025.109503 · Cited by 8
Wang, H., He, R., Deng, L., He, J., & Shen, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1590128 · Cited by 8
Xu, G., Fang, B., Tang, X., Wei, Q., & Li, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s531641 · Cited by 8
Asif, P. J., Borghuis, L. H., van Hooff, S. R., Grootemaat, A. E., van Eijndhoven, M. A. J., de Rooij, J., Groenewegen, N. J., Pérez‐Boza, J., Kranenburg, O., Rinkes, I. H. M. B., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70171 · Cited by 9
New Developments in Sparse PLS Regression
Magnanensi, J., Maumy‐Bertrand, M., Meyer, N., & Bertrand, F. (2021) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2021.693126 · Cited by 8
Xu, H., Wu, A., Ren, H., Yu, C., Liu, G., & Liu, L. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152057 · Cited by 8
Hou, Y., Zhang, F., Zong, J., Li, T., Gan, W., Lv, S., Yan, Z., Zeng, Z., Yang, L., Zhou, M., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01981-2 · Cited by 8
Zhang, Q., Wu, W., Guo, F., Li, J., Jin, Y., Cai, G., & Yang, Y. (2024) · Microorganisms · doi:10.3390/microorganisms12071319 · Cited by 8
Zhao, Z., Miao, Z., Hou, Y., Zhong, Y., Zhang, X., & Fang, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112691 · Cited by 8
Zhang, L., Li, Y., Fu, C., Yang, L., Li, G., Wu, Y., Tong, H., Tian, G., Wang, K., Wang, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71465-5 · Cited by 8
Palaniappan, A., Muthamilselvan, S., & Sarathi, A. (2024) · PeerJ · doi:10.7717/peerj.18347 · Cited by 8
Zhang, W., Wu, C., Huang, H., Bleu, P., Zambare, W. V., Alvarez, J. A., Wang, L., Paty, P. B., Romesser, P. B., Smith, J. J., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2024.102238 · Cited by 8
Kim, S.-Y., Kang, M., Jeong, S., Kim, J., Kim, K. O., Lee, W., Baek, J., Kim, J. H., & Nam, S. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70010 · Cited by 8
Gao, M., Qian, J., Xia, P., Liu, W., Jiang, Y., Xia, Y., Yao, X., Jiao, Q., & Wei, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593639 · Cited by 8
Prognostic Value of FBXO39 and ETS-1 but not BMI-1 in Iranian Colorectal Cancer Patients
Motalebzadeh, J., Shabani, S., Rezayati, S., Shakournia, N., Mirzaei, R., Mahjoubi, B., Hoseini, K., & Mahjoubi, F. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.5.1357 · Cited by 8
Dong, C., Cui, D.-N., Liu, G., Xu, H., Peng, X., Duan, J., & Liu, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9533 · Cited by 8
Development and validation of a five‐lncRNA signature with prognostic value in colon cancer
Lv, J., Guo, Y., Yan, L., Yang, L., Liu, D., & Niu, J. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29518 · Cited by 8
Zhang, C., Zhao, Z., Liu, H., Yao, S., & Zhao, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.657658 · Cited by 8
Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer
Zhang, Y., Zhang, K., Gong, H., Li, Q., Man, L., Jin, Q., Zhang, L., & Song, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.807129 · Cited by 8
Lv, L., Huang, Y., Li, Q., Wu, Y., & Zheng, L. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241258570 · Cited by 8
Robinson, S. C., Donaldson, N. S., Dvorkin‐Gheva, A., Longo, J., He, L., & Daniel, J. M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.007 · Cited by 8
Formica, V., Zaniboni, A., Loupakis, F., & Roselli, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31616 · Cited by 8
Hu, J., Yue, X., Liu, J., & Kong, D. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9505 · Cited by 8
Hentzen, J. E. K. R., van der Plas, W. Y., Kuipers, H., Ramcharan, S., Been, L. B., Hoogwater, F. J. H., van Ginkel, R. J., van Dam, G. M., Hemmer, P. H. J., & Kruijff, S. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.11.515 · Cited by 8
Li, Q., Dai, W., Liu, J., Sang, Q., Li, Y., & Li, Y. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa041 · Cited by 8
Ward, E. P., Evans, D. B., & Tsai, S. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26395 · Cited by 8
Liu, J., Li, Y., Gan, Y., Xiao, Q., Tian, R., Shu, G., & Yin, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.671211 · Cited by 8
Palassin, P., Lapierre, M., Pyrdziak, S., Wagner, A., Stehle, R., Corsini, C., Duffour, J., Bonnet, S., Boulahtouf, A., Rodríguez, C., et al. (2021) · Cancers · doi:10.3390/cancers13174449 · Cited by 8
Self-citationKozakiewicz, C. P., Fraik, A. K., Patton, A. H., Ruiz‐Aravena, M., Hamilton, D. G., Hamede, R., McCallum, H. I., Hohenlohe, P. A., Margres, M. J., Jones, M. E., et al. (2021) · BMC Genomics · doi:10.1186/s12864-021-07994-4 · Cited by 8
Integrating genomic signatures for treatment selection with Bayesian predictive failure time models
Ma, J., Hobbs, B. P., & Stingo, F. C. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280216675373 · Cited by 8
Qiu, Y., Jiang, H., Ching, W., & Ng, M. K. (2018) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2018.09.005 · Cited by 8
Ye, S., Cheng, Y., Hu, J., Gao, F., & Lan, P. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.112 · Cited by 8
Rocha, D., García, I. A., Montoro, A. M. G., Llera, A. S., Prato, L. B., Girotti, M. R., Soria, G., & Fernández, E. A. (2020) · Cells · doi:10.3390/cells10010045 · Cited by 8
Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
Nyamundanda, G., Fontana, E., & Sadanandam, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz294 · Cited by 8
Translating Translational Research into Global Health Gains
Editors, T. P. M. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001493 · Cited by 8
Deciphering tryptophan metabolism in colorectal cancer through multi-omics analysis
Zhang, C., Rao, Z., Zhan, X., Qin, J., Yang, L., Yin, Q., Ji, J., Zhao, X., Liu, Y., Lu, Z., et al. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102157 · Cited by 7
New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review)
Xie, D., Xie, L., Fang, C., Du, Z., Cao, Z., Su, C., & Huo, Y. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5617 · Cited by 7
Lv, X., Ma, W., Miao, X., Hu, S., & Xie, H. (2024) · Environmental Toxicology · doi:10.1002/tox.24214 · Cited by 7
NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage
Alonso‐Marañón, J., Solé, L., Villanueva, D. A., Maqueda, M., Lobo‐Jarne, T., Montoto, Á., Yélamos, J., Borràs, E., Uraga, L., Hooper, C., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adr0128 · Cited by 7
Liu, L., Wu, M., Chen, Y., Cheng, Y., Liu, S., Zhang, X., Xie, Q., Cao, L., Wei, L., Fang, Y., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5522 · Cited by 7
Zhang, J., Jin, X., Hou, Y., Gu, B., Li, H., Yi, L., Wu, W., & Hu, S. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01405-x · Cited by 7
Zheng, C., Zhu, B., Chen, Y., Shahid, N., Hu, Y., Husain, H. M. A. A., Ou, B., Zhang, Q., Jin, H., Zheng, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622528 · Cited by 7
Suzuki, H., Okayama, H., Nakajima, S., Saito, K., Kanoda, R., Maruyama, Y., Matsuishi, A., Matsumoto, T., Ito, M., Chida, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0270 · Cited by 7
Large Scale Statistical Analysis of GEO Datasets
Ycart, B. (2014) · Gene Technology · doi:10.4172/2329-6682.1000113 · Cited by 7
Translating Genomic Profiling to Gastrointestinal Cancer Treatment
Harada, K., Kaya, D. M., Shimodaira, Y., Song, S., Baba, H., & Ajani, J. A. (2017) · Future Oncology · doi:10.2217/fon-2016-0422 · Cited by 7
Hypermutated tumours across 11 cancer types show three distinct immune subtypes
Hu, W., Chen, J., Qi, L., Ge, W., Zheng, S. S., & Yang, Y. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.044 · Cited by 7
Alorda-Clara, M., Torrens‐Mas, M., Hernández‐López, R., de la Rosa, J. M. I., Falcó, E., Fernández, T., Sastre‐Serra, J., Oliver, J., Pons, D. G., & Roca, P. (2022) · Cancers · doi:10.3390/cancers14184487 · Cited by 7
Li, K., Liu, Y., Han, J.-G., Gui, J., & Zhang, X. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0262 · Cited by 7
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.